Researchers at Korea Research Institute of Bioscience and Biotechnology developed a nanobody-based therapy enabling highly selective targeting of lung cancer cells. This technology offers unprecedented precision and therapeutic potential by leveraging engineered nanobodies with enhanced tumor specificity and minimal off-target effects. The approach heralds a new phase in precision oncology, augmenting treatment options for one of the deadliest cancers.